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Trastuzumab単剤療法が著効した切除不能進行胃癌の１例
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SUMMARY
Trastuzumab, a humanized monoclonal antibody directed against human epidermal growth
factor receptor２（HER２）, has been shown to be active against metastatic gastric cancer that over-
express HER２. A７８-year-old man presented with an edema in the lower legs. He was diagnosed
as having advanced gastric cancers with multiple liver metastases in our hospital. Immunohisto-
chemistry of the tumor cells revealed HER２overexpression with an intensity of３＋. The patient
was treated with DS-T chemotherapy（Docetaxel＋S‐１＋Trastuzumab）because of the presence of
renal dysfunction. Due to the adverse effect appeared with his skin, DS-T chemotherapy has been
canceled and trastuzumab chemotherapy was continued. After１１months of trastuzumab mono-
therapy, metastatic liver tumors were diminished. There is very few report of a positive response
to trastuzumab in a patient with HER２‐overexpressing metastatic gastric cancer.
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